Overview
Two decades since the introduction of the first pneumococcal conjugate vaccine in children, there are still many countries including Saudi Arabia with incomplete documentation of the burden of pneumococcal disease serotype epidemiology. This significant gap hinders the ability to make informed evaluations of disease burden and evolving epidemiology.
Project Types and Area of Interest
Potential applicants are encouraged to address pneumococcal disease epidemiology in the pediatric population utilizing surveillance methods (prospective or bidirectional cohort). This may include:
• Surveillance studies addressing invasive and non-invasive pneumococcal disease serotype distribution in pediatric population less than 5 years of age.Sample sources should be obtained between 2023 till end of 2029 and include, but are not limited to, sterile sites such as blood, cerebrospinal fluid, and pleural fluid in children with suspected invasive pneumococcal disease as well as middle ear specimens from ear tube placement or eardrum rupture, used to assess circulating serotypes.
• Genetic evolution of pneumococci following immunization programs with PCV.
• Antibiotic sensitivity information of S. pneumoniae in children less than 5 years of age.
Funding Range and Project Length
Individual projects requesting up to 400,000 USD will be considered. Projects costing higher than this may be considered on a case-by-case basis. The maximum project length is 3 years.
👉 Misalignment with Pfizer’s current RFP (Request for Proposals) is a major rejection factor
Pfizer strongly favors proposals that demonstrate:
👉 Compared to academic grants, practical impact is more heavily weighted
Successful applications typically include:
👉 Weak methodology is one of the most common rejection reasons
👉 Early-career applicants can succeed, but usually with:
For Pfizer grants (especially IIR):
👉 Non-compliance can lead to automatic disqualification
Highest impact factors:
Moderate predictors:
4. Investigator track record
5. Institutional capability
6. Feasibility
Supporting factors:
7. Budget clarity
8. Compliance
9. Independence & transparency
Unlike Horizon Europe or NIH-type grants:
👉 Pfizer funding is more application-driven than theory-driven
👉 “Will this improve patient care soon?” is the central evaluation lens
• The institution and Principal Investigator (PI) must be based in Saudi Arabia as noted above.
• Only organizations are eligible to receive grants. Multicenter collaboration is encouraged.
• Individuals or medical practice groups (i.e., an independent group of physicians not affiliated with a hospital, academic institution, or professional society) are not eligible to receive grants.
• If the project involves multiple departments within an institution and/or between different institutions / organizations / associations, all institutions must have a relevant role and the requesting organization must have a key role in the project.
• The PI must have a medical or postdoctoral degree (MD, PhD, or equivalent), an advanced nursing degree (BSN with a MS/PhD), or a degree in Pharmacy.
• The applicant must be the PI or an authorized designee of such individual (e.g., PI’s research coordinator).
• The PI must be an employee or contractor of the requesting organization.
• Requesting organization must be legally able to receive award funding directly from Pfizer International LLC. We strongly recommend that applicants confirm this with their organization or institution prior to submitting an application. Grants awarded to organizations that are subsequently found to be unable to accept funding directly from Pfizer International LLC may be subject to rescission.
Eligible Countries:
Sponsor Institute/Organizations: Pfizer
Sponsor Type: Corporate/Non-Profit
Address: 66 Hudson Boulevard East, New York, NY 10001-2192
Affiliation Disclaimer: Trialect operates independently and is not affiliated with, endorsed by, or supported by any sponsors or organizations posting on the GrantsBoard platform. As an independent aggregator of publicly available funding opportunities, Trialect provides equal access to information for all users without endorsing any specific funding source, content, organization, or sponsor. Trialect assumes no responsibility for the content posted by sponsors or third parties.
Subscription Disclaimer: Upon logging into Trialect, you may choose to SUBSCRIBE to GrantsBoard for timely notifications of funding opportunities and to access exclusive benefits, such as priority alerts, reminders, personalized recommendations, and additional application support. However, users are advised to contact sponsors directly for any questions and are not required to subscribe to engage with funding opportunities.
Content Ownership and Copyright Disclaimer: Trialect respects the intellectual property rights of all organizations and individuals. All content posted on GrantsBoard is provided solely for informational purposes and remains the property of the original owners. Trialect does not claim ownership of, nor does it have any proprietary interest in, content provided by third-party sponsors. Users are encouraged to verify content and ownership directly with the posting sponsor.
Fair Use Disclaimer: The information and content available on GrantsBoard are compiled from publicly accessible sources in alignment with fair use principles under U.S. copyright law. Trialect serves as an aggregator of this content, offering it to users in good faith and with the understanding that it is available for public dissemination. Any organization or individual who believes their intellectual property rights have been violated is encouraged to contact us for prompt resolution.
Third-Party Posting Responsibility Disclaimer: Trialect is a neutral platform that allows third-party sponsors to post funding opportunities for informational purposes only. Sponsors are solely responsible for ensuring that their postings comply with copyright, trademark, and other intellectual property laws. Trialect assumes no liability for any copyright or intellectual property infringements in third-party content and will take appropriate action to address any substantiated claims.
Accuracy and Verification Disclaimer: Trialect makes no warranties regarding the accuracy, completeness, or reliability of the information provided by sponsors. Users are advised to verify the details of any funding opportunity directly with the sponsor before taking action. Trialect cannot be held liable for any discrepancies, omissions, or inaccuracies in third-party postings.
Notice and Takedown Policy: Trialect is committed to upholding copyright law and protecting the rights of intellectual property owners. If you believe that content on GrantsBoard infringes your copyright or intellectual property rights, please contact us with detailed information about the claim. Upon receipt of a valid notice, Trialect will promptly investigate and, where appropriate, remove or disable access to the infringing content.
Jun 01, 2026
Jun 01, 2026
$400,000
Affiliation: Pfizer
Address: 66 Hudson Boulevard East, New York, NY 10001-2192
Disclaimer:It is mandatory that all applicants carry workplace liability insurance, e.g., https://www.protrip-world-liability.com (Erasmus students use this package and typically costs around 5 € per month - please check) in addition to health insurance when you join any of the onsite Trialect partnered fellowships.